Matches in Wikidata for { <http://www.wikidata.org/entity/Q91861251> ?p ?o ?g. }
Showing items 1 to 75 of
75
with 100 items per page.
- Q91861251 description "2019 թվականի հուլիսի 11-ին հրատարակված գիտական հոդված" @default.
- Q91861251 description "artículu científicu espublizáu en xunetu de 2019" @default.
- Q91861251 description "im Juli 2019 veröffentlichter wissenschaftlicher Artikel" @default.
- Q91861251 description "scientific article published on 11 July 2019" @default.
- Q91861251 description "wetenschappelijk artikel" @default.
- Q91861251 description "наукова стаття, опублікована 11 липня 2019" @default.
- Q91861251 name "Incremental Utility of Adjuvant Chemotherapy in Muscle-invasive Bladder Cancer: Quantifying the Relapse Risk Associated with Therapeutic Effect" @default.
- Q91861251 name "Incremental Utility of Adjuvant Chemotherapy in Muscle-invasive Bladder Cancer: Quantifying the Relapse Risk Associated with Therapeutic Effect" @default.
- Q91861251 type Item @default.
- Q91861251 label "Incremental Utility of Adjuvant Chemotherapy in Muscle-invasive Bladder Cancer: Quantifying the Relapse Risk Associated with Therapeutic Effect" @default.
- Q91861251 label "Incremental Utility of Adjuvant Chemotherapy in Muscle-invasive Bladder Cancer: Quantifying the Relapse Risk Associated with Therapeutic Effect" @default.
- Q91861251 prefLabel "Incremental Utility of Adjuvant Chemotherapy in Muscle-invasive Bladder Cancer: Quantifying the Relapse Risk Associated with Therapeutic Effect" @default.
- Q91861251 prefLabel "Incremental Utility of Adjuvant Chemotherapy in Muscle-invasive Bladder Cancer: Quantifying the Relapse Risk Associated with Therapeutic Effect" @default.
- Q91861251 P1433 Q91861251-C81861C3-FC4A-43E2-A3D8-D46668DFAD77 @default.
- Q91861251 P1476 Q91861251-35A2DDC1-3BCC-4E59-A28A-16EEB33E9B9E @default.
- Q91861251 P2093 Q91861251-190E121A-7B17-4020-8687-BBB42A783A3E @default.
- Q91861251 P2093 Q91861251-354F3A6E-6F02-402A-BDA6-723B7CB14260 @default.
- Q91861251 P2093 Q91861251-69B9FAC5-69F1-44DB-B31B-AF350CA90692 @default.
- Q91861251 P2093 Q91861251-6B87FB44-6460-4087-A2A2-26E8FEC35395 @default.
- Q91861251 P2093 Q91861251-C9E472BE-C5A1-4980-940B-7D1E9417D94A @default.
- Q91861251 P2093 Q91861251-CAB97E34-C1E8-443A-AE01-0E25572EFD54 @default.
- Q91861251 P304 Q91861251-5CEB46A5-D39C-4E0C-946F-915AD9634A32 @default.
- Q91861251 P31 Q91861251-BE9212CB-454C-40A9-9115-427B33412138 @default.
- Q91861251 P356 Q91861251-0387F981-C2F1-4AF1-AD0F-8C031992D611 @default.
- Q91861251 P433 Q91861251-A9BAE961-D7E4-40ED-A696-DF0A00001D1B @default.
- Q91861251 P478 Q91861251-5B4566CC-997B-4F16-9521-7F73D6337FA8 @default.
- Q91861251 P50 Q91861251-060F52E2-5499-41FA-A0CB-38F9AB5B252D @default.
- Q91861251 P50 Q91861251-1C19A6E8-FC43-4110-99F5-B93FD6869CE3 @default.
- Q91861251 P50 Q91861251-4D813C8D-05A7-4BEE-B691-C254CF8882C7 @default.
- Q91861251 P50 Q91861251-64204E4B-E81A-4BF1-AEEE-259EA94230B7 @default.
- Q91861251 P50 Q91861251-6D6FA678-3E90-424E-8494-BB3AD3C33AC7 @default.
- Q91861251 P50 Q91861251-75293AF7-ACC2-426D-8B7C-21DCF8568E38 @default.
- Q91861251 P50 Q91861251-7D3E1A98-5FE0-4CBB-B421-07959A469A07 @default.
- Q91861251 P50 Q91861251-9CBAC041-8AC0-44D8-A8C0-423ABB1E1D37 @default.
- Q91861251 P50 Q91861251-A5CDFCAF-FAB1-4DA7-AEC1-A6773B8BC478 @default.
- Q91861251 P50 Q91861251-A7404E1A-28AD-4F1E-8F89-6211A82D375D @default.
- Q91861251 P50 Q91861251-B03A87F0-6B8F-438B-995F-664AC39AEB0D @default.
- Q91861251 P50 Q91861251-B836B256-AFC7-4A25-A525-5DD81296CDC8 @default.
- Q91861251 P50 Q91861251-DDBCE050-EC05-42C2-9A33-B6DFDDF2DC49 @default.
- Q91861251 P50 Q91861251-EEFCCA67-9DCB-43AD-879C-86609BE5BA33 @default.
- Q91861251 P50 Q91861251-EF7FA7FE-00A8-4E31-B435-B9C6A60CEF2D @default.
- Q91861251 P577 Q91861251-E2E79344-320F-4AB2-871E-C8FC58A5133B @default.
- Q91861251 P698 Q91861251-133698B4-9CCC-4BD0-8DC1-FA5565731E51 @default.
- Q91861251 P356 J.EURURO.2019.06.032 @default.
- Q91861251 P698 31303258 @default.
- Q91861251 P1433 Q15763991 @default.
- Q91861251 P1476 "Incremental Utility of Adjuvant Chemotherapy in Muscle-invasive Bladder Cancer: Quantifying the Relapse Risk Associated with Therapeutic Effect" @default.
- Q91861251 P2093 "Andrea Gallina" @default.
- Q91861251 P2093 "Christine Théodore" @default.
- Q91861251 P2093 "Evan Y Yu" @default.
- Q91861251 P2093 "Lauren C Harshman" @default.
- Q91861251 P2093 "Neeraj Agarwal" @default.
- Q91861251 P2093 "RISC Investigators" @default.
- Q91861251 P304 "425-429" @default.
- Q91861251 P31 Q13442814 @default.
- Q91861251 P356 "10.1016/J.EURURO.2019.06.032" @default.
- Q91861251 P433 "4" @default.
- Q91861251 P478 "76" @default.
- Q91861251 P50 Q41492572 @default.
- Q91861251 P50 Q42687629 @default.
- Q91861251 P50 Q42862184 @default.
- Q91861251 P50 Q42869865 @default.
- Q91861251 P50 Q57011007 @default.
- Q91861251 P50 Q67191520 @default.
- Q91861251 P50 Q67191563 @default.
- Q91861251 P50 Q86981393 @default.
- Q91861251 P50 Q87736790 @default.
- Q91861251 P50 Q88251851 @default.
- Q91861251 P50 Q89342100 @default.
- Q91861251 P50 Q89687397 @default.
- Q91861251 P50 Q89714924 @default.
- Q91861251 P50 Q91886243 @default.
- Q91861251 P50 Q96608941 @default.
- Q91861251 P577 "2019-07-11T00:00:00Z" @default.
- Q91861251 P698 "31303258" @default.